Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Core Insights - Hoth Therapeutics is adopting Lantern Pharma's PredictBBB.ai platform, which boasts a 94% accuracy in predicting blood-brain barrier permeability, positioning the company at the forefront of AI-driven drug development [1][2][3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments aimed at improving patient quality of life [5] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [5] Strategic Impact - The integration of PredictBBB.ai allows Hoth to enhance precision in candidate selection, reduce development risks, and potentially create faster regulatory pathways for its drug pipeline [4] - The ability to cross the blood-brain barrier is identified as a critical success factor for drug candidates, and the AI tool is expected to streamline this process [4] Leadership Statements - Hoth's CEO, Robb Knie, highlighted the commitment to utilizing disruptive technologies like AI to drive efficiency and unlock new opportunities for patients and shareholders [5] - Lantern Pharma's CEO, Panna Sharma, expressed enthusiasm for the collaboration, noting the potential of PredictBBB.ai to accelerate CNS drug development [3]